Correspondence 0001104659-23-074162 from AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: June 23, 2023 · CIK: 0001644963 · Accession: 0001104659-23-074162
AI Filing Summary & Sentiment
File numbers found in text: 333-272730
Letter
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154
VIA EDGAR
June 23, 2023
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Alan Campbell
Re: Avenue Therapeutics, Inc.
Registration Statement on Form S-3 (File. No. 333-272730)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (as amended, the “Registration Statement”) so that the Registration Statement will be declared effective as of 4:30 p.m. Eastern time, on June 27, 2023, or at such other time as the Company or its outside counsel, McGuireWoods LLP, may request via a telephone call to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with David Wolpa of McGuireWoods LLP at (704) 343-2185, or in his absence, Rakesh Gopalan of McGuireWoods LLP at (704) 343-2275.
Thank you for your assistance in this matter.
Sincerely,
Avenue Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301, Bay Harbor
Islands, FL 33154
VIA EDGAR
June 23, 2023
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Alan Campbell
Re:
Avenue Therapeutics, Inc.
Registration Statement
on Form S-3 (File. No. 333-272730)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the
Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration
Statement on Form S-3 (as amended, the “Registration Statement”) so that the Registration Statement will be declared
effective as of 4:30 p.m. Eastern time, on June 27, 2023, or at such other time as the Company or its outside counsel, McGuireWoods
LLP, may request via a telephone call to the staff of the Commission.
Once the Registration
Statement has been declared effective, please orally confirm that event with David Wolpa of McGuireWoods LLP at (704) 343-2185, or
in his absence, Rakesh Gopalan of McGuireWoods LLP at (704) 343-2275.
Thank you for your assistance
in this matter.
Sincerely,
Avenue Therapeutics, Inc.
/s/ Alexandera MacLean
Alexandra MacLean, Chief Executive Officer